Fig 1: MRPL12 knockdown suppressed cell proliferation and invasion in LUAD. (A) MRPL12 mRNA expression in A549 and PC9 cells after sh-MRPL12 transfection. (B) Sh-MRPL12 inhibited LUAD cell growth according to CCK-8. (C) Sh-MRPL12 inhibited colony number of LUAD cells according to the colony formation assay. (D) Sh-MRPL12 reduced wound closure percent of LUAD cells according to wound-healing assay. (E,F) Sh-MRPL12 suppressed cell migration and invasion in LUAD according to Transwell assays. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, no significance.
Fig 2: Correlation between MRPL12 expression and prognosis of LUAD patients from TMA. (A) IHC images of MRPL12 in LUAD and matched normal tissues. (B) IHC score of MRPL12 was higher in LUAD tissues. (C) High MRPL12 expression in LUAD patients was related to worse survival. (D) IHC score of patients with metastasis was higher than that of patients without metastasis. * p < 0.05, *** p < 0.001.
Fig 3: GO and KEGG pathway enrichment analysis of MRPL12 in LUAD. (A) PPI network of MRPL12 with its interactive genes from GeneMANIA database. (B) Volcano plot of all genes correlated with MRPL12 in LUAD from LinkedOmics database. (C,D) Heatmaps of top 50 significant genes positively and negatively correlated with MRPL12. (E) GO analysis of MRPL12 in LUAD. (F) KEGG pathway analysis of MRPL12 in LUAD.
Fig 4: MRPL12 mRNA expression level in LUAD. (A) MRPL12 mRNA level was upregulated in various types of malignancies from TIMER database, including LUAD. (B) MRPL12 mRNA level was markedly increased in LUAD tissues from UALCAN database. (C–E) MRPL12 mRNA level was overexpressed in LUAD samples compared with normal samples, as analyzed by patients’ gender, cancer stage, and nodal metastasis status. Multiple group comparisons were performed with ANOVA followed by the Bonferroni post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Fig 5: Correlation between MRPL12 expression and immunomodulators in LUAD. (A) Heatmap of correlations between MRPL12 and immunoinhibitors across different cancers from TISIDB. (B) Relationships between MRPL12 and immunoinhibitors (including BTLA, CD96, CSF1R, IL10, KDR, and TGFB1) in LUAD. (C) Heatmap of correlations between MRPL12 and immunostimulators across different cancers. (D) Relationships between MRPL12 and immunostimulators (including CD28, CD40LG, CXCL12, IL6R, TMEM173, and TNFSF15) in LUAD.
Supplier Page from Abcam for Anti-MRPL12 antibody